Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HMPL-523 in Relapsed or Refractory Lymphoma
NCT03779113Phase 1Terminated
- Sponsor
- HUTCHMED
- Start
- Sep 2019
- Primary completion
- Feb 2025
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 1, open-label trial of sovleplenib in lymphoma, sponsored by HUTCHMED. Primary endpoints: Number of Patients With Dose-Limiting Toxicities at 28 days, Number of Patients With Treatment-Emergent Adverse Events at 29 months and 7 more. Started Sep 2019; status: terminated.
02
Drugs
sovleplenib
03
Conditions
lymphoma
Beyond the preview
Go deeper on NCT03779113.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03779113.